Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors
Christopher Heeschen, … , Stefanie Dimmeler, John P. Cooke
Christopher Heeschen, … , Stefanie Dimmeler, John P. Cooke
Published August 15, 2002
Citation Information: J Clin Invest. 2002;110(4):527-536. https://doi.org/10.1172/JCI14676.
View: Text | PDF
Article Vascular biology

A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors

  • Text
  • PDF
Abstract

Research Article

Authors

Christopher Heeschen, Michael Weis, Alexandra Aicher, Stefanie Dimmeler, John P. Cooke

×

Figure 6

Options: View larger image (or click on image) Download as PowerPoint
Lewis lung tumor model: mecamylamine inhibits advanced tumor growth. Two...
Lewis lung tumor model: mecamylamine inhibits advanced tumor growth. Two weeks after subcutaneous injection of Lewis lung cancer cells, tumor growth was similar in the control and mecamylamine groups. In the subsequent study period, however, animals treated with mecamylamine showed significantly less tumor growth. Data are median (95% CI); n = 5; P < 0.01 compared with control at 24 days. Tumor vascularity was suppressed by mecamylamine (data not shown).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts